Abstract
Multiple myeloma is an incurable B cell neoplasm caused by the monoclonal expansion of malignant plasma cells in the bone marrow, often resulting in devastating bone disease. For over 2 decades bisphosphonates have been successfully used to treat the tumourinduced bone disease associated with multiple myeloma. This review will focus on preclinical studies and investigations in patients with multiple myeloma that have led to our current understanding of the mechanisms of action of bisphosphonates in myeloma bone disease. Major advances in the use of bisphosphonates, including findings that they may have additional benefits such as anti-tumour effects and promoting patient survival will be discussed.
Keywords: Bisphosphonates, myeloma, anti-resorptive, anti-tumour, bone, osteoclasts, osteolytic lesions, Multiple Myeloma, M-spike, M-protein, Bence-Jones Protein, lymphatohaemopoietic cancer, Osteoclast-derived molecules, dickkopf-1 (DKK1), frizzled-related protein (sFRP)-2, myeloma-derived DKK1, MM-derived osteoclasts, anti-DKK1, OSTEOCLAST INHIBITION, clodronate (CLOD), etidronate (ETID), protein prenylation, bone mineral density (BMD), Anti-Tumour Effects, anti-resorptive potency, SCID-hu model, Angiogenesis, Bisphosphoante-Associated Osteonecrosis of the Jaw (BONJ), vascular insufficiency, B-cell activating factor, Hepatocyte growth factor, Interleukin 1 alpha
Current Pharmaceutical Design
Title: Bisphosphonate Therapy in the Treatment of Multiple Myeloma
Volume: 16 Issue: 27
Author(s): M. A. Lawson, J. Ashcroft and P. I. Croucher
Affiliation:
Keywords: Bisphosphonates, myeloma, anti-resorptive, anti-tumour, bone, osteoclasts, osteolytic lesions, Multiple Myeloma, M-spike, M-protein, Bence-Jones Protein, lymphatohaemopoietic cancer, Osteoclast-derived molecules, dickkopf-1 (DKK1), frizzled-related protein (sFRP)-2, myeloma-derived DKK1, MM-derived osteoclasts, anti-DKK1, OSTEOCLAST INHIBITION, clodronate (CLOD), etidronate (ETID), protein prenylation, bone mineral density (BMD), Anti-Tumour Effects, anti-resorptive potency, SCID-hu model, Angiogenesis, Bisphosphoante-Associated Osteonecrosis of the Jaw (BONJ), vascular insufficiency, B-cell activating factor, Hepatocyte growth factor, Interleukin 1 alpha
Abstract: Multiple myeloma is an incurable B cell neoplasm caused by the monoclonal expansion of malignant plasma cells in the bone marrow, often resulting in devastating bone disease. For over 2 decades bisphosphonates have been successfully used to treat the tumourinduced bone disease associated with multiple myeloma. This review will focus on preclinical studies and investigations in patients with multiple myeloma that have led to our current understanding of the mechanisms of action of bisphosphonates in myeloma bone disease. Major advances in the use of bisphosphonates, including findings that they may have additional benefits such as anti-tumour effects and promoting patient survival will be discussed.
Export Options
About this article
Cite this article as:
A. Lawson M., Ashcroft J. and I. Croucher P., Bisphosphonate Therapy in the Treatment of Multiple Myeloma, Current Pharmaceutical Design 2010; 16 (27) . https://dx.doi.org/10.2174/138161210793563608
DOI https://dx.doi.org/10.2174/138161210793563608 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recent Advances for Cell / Gene Therapy in Rheumatoid Arthritis
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Molecular Profiles of Sentinel and Non-Sentinel Lymph Nodes in Breast Cancer Progression and Prognosis
Current Cancer Therapy Reviews Context-dependent Action of Transforming Growth Factor β Family Members on Normal and Cancer Stem Cells
Current Pharmaceutical Design Upstream Processing of Plasmid DNA for Vaccine and Gene Therapy Applications
Recent Patents on Biotechnology Exploring Proteomic Drug Targets, Therapeutic Strategies and Protein - Protein Interactions in Cancer: Mechanistic View
Current Cancer Drug Targets Involvement of Cannabinoids in Cellular Proliferation
Mini-Reviews in Medicinal Chemistry Stable Expression of the Sodium/Iodide Symporter (NIS) for anti-Cancer Gene Therapy of Glioma Cells Using a Third Generation Self-Inactivating Lentiviral Vector System in Combination with 211At
Current Radiopharmaceuticals Meet Our Editorial Board Member:
Protein & Peptide Letters Mevalonate Pathway and Human Cancers
Current Molecular Pharmacology From Na+/K+-ATPase and Cardiac Glycosides to Cytotoxicity and Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry Epidemiology of Candida albicans Infections and Role of Non-Candidaalbicans Yeasts
Current Drug Targets 1,2,3-Triazine Scaffold as a Potent Biologically Active Moiety: A Mini Review
Mini-Reviews in Medicinal Chemistry The Chemistry and Bio-Medicinal Significance of Pyrimidines & Condensed Pyrimidines
Current Topics in Medicinal Chemistry Azathioprine in Multiple Sclerosis
Mini-Reviews in Medicinal Chemistry Mechanism-based Combinations with Pim Kinase Inhibitors in Cancer Treatments
Current Pharmaceutical Design Anionic Host Defence Peptides from the Plant Kingdom: Their Anticancer Activity and Mechanisms of Action
Protein & Peptide Letters Interferon-α Treatment in Systemic Mastocytosis
Current Drug Targets Interleukin-24: A Molecule with Potential Anti-Cancer Activity and a Cytokine in Search of a Function
Endocrine, Metabolic & Immune Disorders - Drug Targets Cancer Prevention with Promising Natural Products: Mechanisms of Action and Molecular Targets
Anti-Cancer Agents in Medicinal Chemistry Protein-Protein Interaction Inhibitors: Small Molecules from Screening Techniques
Current Topics in Medicinal Chemistry